KOPRAN · Healthcare · Drug Manufacturers - General
| Share price | ₹217.83 |
| Market cap | ₹1,052 Cr |
| P/E ratio | 42.0 |
| P/B ratio | 2.0 |
| ROE | 10.6% |
| ROCE | 7.7% |
| Dividend yield | 1.49% |
| Book value | ₹109.82 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹676 Cr | ₹26 Cr | 9.0% |
| 2025 | ₹624 Cr | ₹39 Cr | 9.2% |
| 2024 | ₹615 Cr | ₹51 Cr | 10.0% |
| 2023 | ₹548 Cr | ₹27 Cr | 8.3% |
| 2022 | — | — | — |
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gast